Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Amyloidosis × belantamab mafodotin × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 27 Recurrence 4 Renal Insufficiency 1 Kidney Failure, Chronic 1 Immunoglobulin Light-chain Amyloidosis 1 Amyloidosis 1

Interventions

miridesap 3 Dexamethasone 2 venetoclax 1 ixazomib 1 birtamimab 1 belantamab mafodotin 1 Pharmaceutical Preparations 1 Lisaftoclax 1 GTP Cyclohydrolase 1 Drug Evaluation 1 Cyclophosphamide 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07224672 2026-03-17

ALANIS

GlaxoSmithKline

Phase 2 Not yet recruiting

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡